Age-related downregulation of the CaV3.1 T-type calcium channel as a mediator of amyloid beta production

Neurobiology of Aging

Volumn 35, Issue 5, 2014, Pages 1002-1011

  Rice, Rachel A ^a   Berchtold, Nicole C ^a   Cotman, Carl W ^a   Green, Kim N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aging; Alzheimer's disease; Amyloid; APP processing; Calcium; Calpains; T type calcium channel

Indexed keywords

AGING; ALZHEIMER'S DISEASE; AMYLOID; APP PROCESSING; CALCIUM; CALPAINS; T-TYPE CALCIUM CHANNEL;

ADULT; AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CALCIUM; CALCIUM CHANNELS, T-TYPE; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HUMANS; KIDNEY; MICE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; RNA, MESSENGER; YOUNG ADULT;

EID: 84893814237     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.10.090     Document Type: Article

References (44)

1. Anders A., Gilbert S., Garten W., Postina R., Fahrenholz F. Regulation of the alpha-secretase ADAM10 by its prodomain and proprotein convertases. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 2001, 15:1837-1839.
2. Anderson M.P., Mochizuki T., Xie J., Fischler W., Manger J.P., Talley E.M., Scammell T.E., Tonegawa S. Thalamic Cav3.1 T-type Ca2+ channel plays a crucial role in stabilizing sleep. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:1743-1748. 10.1073/pnas.0409644102.
3. Anekonda T.S., Quinn J.F., Harris C., Frahler K., Wadsworth T.L., Woltjer R.L. L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease. Neurobiol Dis 2011, 41:62-70. 10.1016/j.nbd.2010.08.020.
4. Astori S., Wimmer R.D., Prosser H.M., Corti C., Corsi M., Liaudet N., Volterra A., Franken P., Adelman J.P., Luthi A. The Ca(V)3.3 calcium channel is the major sleep spindle pacemaker in thalamus. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:13823-13828. 10.1073/pnas.1105115108.
5. Berchtold N.C., Cribbs D.H., Coleman P.D., Rogers J., Head E., Kim R., Beach T., Miller C., Troncoso J., Trojanowski J.Q., Zielke H.R., Cotman C.W. Gene expression changes in the course of normal brain aging are sexually dimorphic. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:15605-15610. 10.1073/pnas.0806883105.
6. Brodie M.J., Ben-Menachem E., Chouette I., Giorgi L. Zonisamide: its pharmacology, efficacy and safety in clinical trials. Acta neurologica Scandinavica Supplementum 2012, 194:19-28. 10.1111/ane.12016.
7. Chakroborty S., Goussakov I., Miller M.B., Stutzmann G.E. Deviant ryanodine receptor-mediated calcium release resets synaptic homeostasis in presymptomatic 3xTg-AD mice. The Journal of neuroscience:. the official journal of the Society for Neuroscience 2009, 29:9458-9470. 10.1523/JNEUROSCI.2047-09.2009.
8. Cribbs D.H., Berchtold N.C., Perreau V., Coleman P.D., Rogers J., Tenner A.J., Cotman C.W. Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. Journal of neuroinflammation 2012, 9:179. 10.1186/1742-2094-9-179.
9. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378:785-789. 10.1038/378785a0.
10. Cruz J.C., Tseng H.C., Goldman J.A., Shih H., Tsai L.H. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 2003, 40:471-483.
11. de Leon M.J., George A.E., Stylopoulos L.A., Smith G., Miller D.C. Early marker for Alzheimer's disease: the atrophic hippocampus. Lancet 1989, 2:672-673.
12. Demuro A., Smith M., Parker I. Single-channel Ca(2+) imaging implicates Abeta1-42 amyloid pores in Alzheimer's disease pathology. The Journal of cell biology 2011, 195:515-524. 10.1083/jcb.201104133.
13. Dogrul A., Gardell L.R., Ossipov M.H., Tulunay F.C., Lai J., Porreca F. Reversal of experimental neuropathic pain by T-type calcium channel blockers. Pain 2003, 105:159-168.
14. Emerick M.C., Stein R., Kunze R., McNulty M.M., Regan M.R., Hanck D.A., Agnew W.S. Profiling the array of Ca(v)3.1 variants from the human T-type calcium channel gene CACNA1G: alternative structures, developmental expression, and biophysical variations. Proteins 2006, 64:320-342. 10.1002/prot.20877.
15. Garcia-Baquero R., Puerta P., Beltran M., Alvarez M., Sacristan R., Alvarez-Ossorio J.L., Sanchez-Carbayo M. Methylation of a Novel Panel of Tumor Suppressor Genes in Urine Moves Forward Non-Invasive Diagnosis and Prognosis in Bladder Cancer: A Two Center Prospective Study. The Journal of urology 2013, 10.1016/j.juro.2013.01.105.
16. Green K.N. Calcium in the initiation, progression and as an effector of Alzheimer's disease pathology. J Cell Mol Med 2009, 13:2787-2799. 10.1111/j.1582-4934.2009.00861.x.
17. Green K.N., Demuro A., Akbari Y., Hitt B.D., Smith I.F., Parker I., LaFerla F.M. SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production. The Journal of cell biology 2008, 181:1107-1116. 10.1083/jcb.200706171.
18. Huang L., Keyser B.M., Tagmose T.M., Hansen J.B., Taylor J.T., Zhuang H., Zhang M., Ragsdale D.S., Li M. NNC 55-0396 [(1S,2S)-2-(2-(N-[(3-benzimidazol-2-yl)propyl]-N-methylamino)ethyl)-6-fluo ro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride]: a new selective inhibitor of T-type calcium channels. J Pharmacol Exp Ther 2004, 309:193-199. 10.1124/jpet.103.060814.
19. Iftinca M.C. Neuronal T-type calcium channels: what's new? Iftinca: T-type channel regulation. J Med Life 2011, 4:126-138.
20. Iritani S., Niizato K., Emson P.C. Relationship of calbindin D28K-immunoreactive cells and neuropathological changes in the hippocampal formation of Alzheimer's disease. Neuropathology: official journal of the Japanese Society of Neuropathology 2001, 21:162-167.
21. Kuhn P.H., Wang H., Dislich B., Colombo A., Zeitschel U., Ellwart J.W., Kremmer E., Rossner S., Lichtenthaler S.F. ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J 2010, 29:3020-3032. 10.1038/emboj.2010.167.
22. Landfield P.W., Pitler T.A. Prolonged Ca2+-dependent afterhyperpolarizations in hippocampal neurons of aged rats. Science 1984, 226:1089-1092.
23. Lopez J.R., Lyckman A., Oddo S., Laferla F.M., Querfurth H.W., Shtifman A. Increased intraneuronal resting [Ca2+] in adult Alzheimer's disease mice. Journal of neurochemistry 2008, 105:262-271. 10.1111/j.1471-4159.2007.05135.x.
24. Maguire-Zeiss K.A., Li Z.W., Shimoda L.M., Hamill R.W. Calbindin D28k mRNA in hippocampus, superior temporal gyrus and cerebellum: comparison between control and Alzheimer disease subjects. Brain research Molecular brain research 1995, 30:362-366.
25. Molloy S.S., Bresnahan P.A., Leppla S.H., Klimpel K.R., Thomas G. Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen. The Journal of biological chemistry 1992, 267:16396-16402.
26. Morioka M., Kawano T., Yano S., Kai Y., Tsuiki H., Yoshinaga Y., Matsumoto J., Maeda T., Hamada J., Yamamoto H., Fukunaga K., Kuratsu J. Hyperphosphorylation at serine 199/202 of tau factor in the gerbil hippocampus after transient forebrain ischemia. Biochemical and biophysical research communications 2006, 347:273-278. 10.1016/j.bbrc.2006.06.096.
27. Oshima T., Ozono R., Yano Y., Higashi Y., Teragawa H., Miho N., Ishida T., Ishida M., Yoshizumi M., Kambe M. Beneficial effect of T-type calcium channel blockers on endothelial function in patients with essential hypertension. Hypertension research: official journal of the Japanese Society of Hypertension 2005, 28:889-894. 10.1291/hypres.28.889.
28. Oules B., Del Prete D., Greco B., Zhang X., Lauritzen I., Sevalle J., Moreno S., Paterlini-Brechot P., Trebak M., Checler F., Benfenati F., Chami M. Ryanodine receptor blockade reduces amyloid-beta load and memory impairments in Tg2576 mouse model of Alzheimer disease. The Journal of neuroscience:. the official journal of the Society for Neuroscience 2012, 32:11820-11834. 10.1523/JNEUROSCI.0875-12.2012.
29. Palop J.J., Jones B., Kekonius L., Chin J., Yu G.Q., Raber J., Masliah E., Mucke L. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:9572-9577. 10.1073/pnas.1133381100.
30. Patrick G.N., Zhou P., Kwon Y.T., Howley P.M., Tsai L.H. p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway. The Journal of biological chemistry 1998, 273:24057-24064.
31. Patrick G.N., Zukerberg L., Nikolic M., de la Monte S., Dikkes P., Tsai L.H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999, 402:615-622. 10.1038/45159.
32. Perez-Reyes E. Molecular physiology of low-voltage-activated t-type calciumchannels. Physiol Rev 2003, 83:117-161. 10.1152/physrev.00018.2002.
33. Quesada A., Bui P.H., Homanics G.E., Hankinson O., Handforth A. Comparison of mibefradil and derivative NNC 55-0396 effects on behavior, cytochrome P450 activity, and tremor in mouse models of essential tremor. European journal of pharmacology 2011, 10.1016/j.ejphar.2011.01.004.
34. Resende R., Ferreiro E., Pereira C., Resende de Oliveira C. Neurotoxic effect of oligomeric and fibrillar species of amyloid-beta peptide 1-42: involvement of endoplasmic reticulum calcium release in oligomer-induced cell death. Neuroscience 2008, 155:725-737. 10.1016/j.neuroscience.2008.06.036.
35. Riascos D., de Leon D., Baker-Nigh A., Nicholas A., Yukhananov R., Bu J., Wu C.K., Geula C. Age-related loss of calcium buffering and selective neuronal vulnerability in Alzheimer's disease. Acta neuropathologica 2011, 122:565-576. 10.1007/s00401-011-0865-4.
36. Rim H.K., Lee H.W., Choi I.S., Park J.Y., Choi H.W., Choi J.H., Cho Y.W., Lee J.Y., Lee K.T. T-type Ca2+ channel blocker, KYS05047 induces G1phase cell cycle arrest by decreasing intracellular Ca2+ levels in humanlung adenocarcinoma A549 cells. Bioorganic & medicinal chemistryletters 2012, 22:7123-7126. 10.1016/j.bmcl.2012.09.076.
37. Sandmann S., Spormann J., Prenzel F., Shaw L., Unger T. Calcium channel blockade limits transcriptional, translational and functional up-regulation of the cardiac calpain system after myocardial infarction. European journal of pharmacology 2002, 453:99-109.
38. Sequier J.M., Hunziker W., Andressen C., Celio M.R. Calbindin D-28k Protein and mRNA Localization in the Rat Brain. The European journal of neuroscience 1990, 2:1118-1126.
39. Splawski I., Yoo D.S., Stotz S.C., Cherry A., Clapham D.E., Keating M.T. CACNA1H mutations in autism spectrum disorders. The Journal of biological chemistry 2006, 281:22085-22091. 10.1074/jbc.M603316200.
40. Stutzmann G.E., Smith I., Caccamo A., Oddo S., Laferla F.M., Parker I. Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer's disease mice. The Journal of neuroscience:. the official journal of the Society for Neuroscience 2006, 26:5180-5189. 10.1523/JNEUROSCI.0739-06.2006.
41. Thibault O., Landfield P.W. Increase in single L-type calcium channels in hippocampal neurons during aging. Science 1996, 272:1017-1020.
42. Toyota M., Ho C., Ohe-Toyota M., Baylin S.B., Issa J.P. Inactivation of CACNA1G, a T-type calcium channel gene, by aberrant methylation of its 5' CpG island in human tumors. Cancer research 1999, 59:4535-4541.
43. Veeranna, Kaji T., Boland B., Odrljin T., Mohan P., Basavarajappa B.S., Peterhoff C., Cataldo A., Rudnicki A., Amin N., Li B.S., Pant H.C., Hungund B.L., Arancio O., Nixon R.A. Calpain mediates calcium-induced activation of the erk1, 2 MAPK pathway and cytoskeletal phosphorylation in neurons: relevance to Alzheimer's disease. The American journal of pathology 2004, 165:795-805. 10.1016/S0002-9440(10)63342-1.
44. Wagner G., Icks A., Abholz H.H., Schroder-Bernhardi D., Rathmann W., Kostev K. Antihypertensive treatment and risk of dementia: a retrospective database study. International journal of clinical pharmacology and therapeutics 2012, 50:195-201.